NanoVibronix Receives FDA 510(k) Premarket Clearance for PainShield Plus (Abomination Shot using Frequency)

https://finance.yahoo.com/news/nanovibronix-receives-fda-510-k-201800174.html#amp_tf=From%20%251%24s&aoh=16697404713835&csi=0&referrer=https%3A%2F%2Fwww.google.com&ampshare=https%3A%2F%2Ffinance.yahoo.com%2Fnews%2Fnanovibronix-receives-fda-510-k-201800174.html

https://www.medicaldevice-network.com/news/nanovibronix-new-ultrasound-pain-management-device/

https://www.medicaldevice-network.com/news/nanovibronix-new-ultrasound-pain-management-device/

ELMSFORD, N.Y., November 28, 2022–(BUSINESS WIRE)–NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company utilizing the Company’s proprietary and patented low intensity surface acoustic wave (SAW) technology, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of its PainShield® MD PLUS, its dual-actuator ultrasound pain therapy device.

Brian Murphy, CEO of NanoVibronix, stated, “Securing 510(k) clearance for PainShield Plus is a key milestone towards achieving permanent clearance from the FDA and full-scale commercial marketability. Increasingly, healthcare providers and patients are seeking effective, non-pharmaceutical therapies for the treatment of chronic pain.

PainShield Plus expands on the effectiveness of its predecessor, our original PainShield M.D., by covering twice the treatment area and broadening the opportunities for application. As a result, we have started the process of making the recommended modifications to the device in order to comply with the FDA standard. In addition, this approval opens the door for us to submit a 510(k) application for our Over-The-Counter product, PainShield Relief, in the near term.”


NanoVibronix Patent – System and method for surface acoustic wave treatment of skin

What is Sonophoresis?

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9041830/

Abstract
Interferons establish an antiviral state through the induction of hundreds of interferon-stimulated genes (ISGs). The mechanisms and viral specificities for most ISGs remain incompletely understood. To enable high-throughput interrogation of ISG antiviral functions in pooled genetic screens while mitigating potentially confounding effects of endogenous interferon and antiproliferative/proapoptotic ISG activities, we adapted a CRISPR-activation (CRISPRa) system for inducible ISG expression in isogenic cell lines with and without the capacity to respond to interferons.


Moderna Patent witb Interferon Drughttps://assets.modernatx.com/m/6fa93a4f95208572/original/US10702600.pdf

Clades mentioned in Moderna Patent and MERS-CoV (Adverse Event from Abomination Shot) with Interferon

WHO renames lineages of monkeypox, moving away from geographic links (CLADE X EXERCISE BEGINS!!)

‘Camel Flu’ Infection Risk For FIFA World Cup Fans: Report (Abomination Shot Adverse Events)


The Depopulation Agenda Plan is commencing..

Please repent, carry your cross daily and accept the free gift of Jesus Christ’s Death on the Cross for payment for your sins.

#Yahweh #Yeshua #HolySpirit #LordAlmighty #SovereignLord #Nameaboveallnames #TheWay #TheTruth #TheLife #TheGate #Heaven #KingdomofHeaven #Saved #Glorified #Endtimes #LastDays #FeastofTrumpets #markofthebeast #verseoftheday #birthpains #Judgement #Christian #Christianity #hope #love #Jesus #Christ

Leave a Reply

Powered by WordPress.com.

Up ↑

%d bloggers like this: